Taxane Therapy

Research led by Fillmore has examined optimal sequencing strategies for taxane therapy in patients with metastatic castration-resistant prostate cancer. His work demonstrates that docetaxel rechallenge provides a significant survival advantage over cabazitaxel for patients who did not progress during their initial docetaxel course. These findings suggest that repeating a previously effective taxane may be a superior second-line therapeutic option for this specific patient population.